You are here

Article info

Article menu

Download PDFPDF

Thursday 06 October 2022 from 13:00 to 14:10
PO.4 E- POSTER SESSION 4: disease activity measurements, flare and remission, epidemiology, etiology, genetics, epigenetics
PO.4.92 Taxonomy, treatment, targets and remission in systemic lupus erythematosus: the 3TR-SLE study protocol

Authors

  • I Parodis Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital ~ Stockholm ~ Sweden PubMed articlesGoogle scholar articles
  • AE Voskuyl Department of Rheumatology and Clinical immunology, Amsterdam University Medical Centre ~ Amsterdam ~ Netherlands PubMed articlesGoogle scholar articles
  • ME Alarcón-Riquelme Area of Medical Genomics, GENYO Centre for Genomics and Oncological Research, University of Granada ~ Spain PubMed articlesGoogle scholar articles
  • L Beretta Referral Center for Systemic Autoimmue Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di MilanoReferral Center for Systemic Autoimmue Diseases, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano ~ Italy PubMed articlesGoogle scholar articles

Citation

Parodis I, Voskuyl A, Alarcón-Riquelme M, et al
PO.4.92 Taxonomy, treatment, targets and remission in systemic lupus erythematosus: the 3TR-SLE study protocol
Lupus Science & Medicine 2022;9:doi: 10.1136/lupus-2022-elm2022.118

Publication history

  • First published September 27, 2022.
Online issue publication 
October 13, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.